Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2022, Propel Bio Partners is a venture capital firm based in Los Angeles and Seattle, dedicated to advancing human health through investments in life science companies. The firm has a target fund size of $150 million and aims to support entrepreneurs developing groundbreaking therapies and technologies. Propel Bio Partners is committed to building ecosystems that empower founders in the life sciences sector, providing not only financial backing but also access to a network of medical experts and operational advisors.
The firm operates with a team of 10 professionals, including General Partners, Analysts, and Advisors, who bring diverse expertise in finance, investment, and life sciences. Propel Bio Partners has quickly established itself in the market, leveraging the extensive backgrounds of its founders and team members to create a strong foundation for future investments. The firm is also listed on the Medical Technology Enterprise Consortium of Southern California's investor directory, highlighting its growing presence in the industry.
Propel Bio Partners specializes in investing in life science companies, particularly in the biotech and healthcare sectors. The firm focuses on supporting the development of disruptive technologies and therapies that can significantly impact human health. Their investment strategy emphasizes the importance of scientific innovation and aims to provide entrepreneurs with the necessary resources to advance their projects.
The firm typically invests in early-stage companies, providing financial support along with access to a robust ecosystem of medical experts and operational advisors. Propel Bio Partners seeks to partner with founders who are passionate about their vision and are committed to improving human health. The firm’s investment thesis revolves around building collaborative environments that facilitate the growth of life science startups, ensuring they have the tools and guidance needed to navigate the complexities of the industry.
Richard Kayne, MBA - General Partner. Richard is a co-founder of Propel Bio Partners and has a background in investment, having founded Kayne Anderson Capital Advisors, a major institutional investment firm.
Leen Kawas, PhD - Managing General Partner. Leen is a co-founder and a biotech entrepreneur, previously serving as the CEO of Athira Pharma, where she led significant advancements in the biotech field.
Xue Hua, PhD - Managing Partner. Xue brings extensive experience in life sciences and investment, contributing to the firm's strategic direction.
Jim Harding, CPA, CMA - Finance. Jim oversees financial operations and ensures the firm’s fiscal health.
Erik Gonzalez-Leon, PhD - Analyst. Erik supports investment analysis and research within the firm.
Sam Berry, PhD - Analyst. Sam focuses on evaluating potential investment opportunities in the life sciences sector.
Joyce Jiang, MPH, PhD - Analyst. Joyce contributes to research and analysis, particularly in healthcare investments.
Safiya Alavi - Associate, Data Science and Research. Safiya aids in data analysis and research initiatives.
Armaan Hirani - Intern. Armaan supports various operational tasks and research projects.
Ron Farkas, MD, PhD - Senior Advisor. Ron provides medical expertise and guidance to the firm.
Sylvia McBrinn, MBA - Senior Advisor. Sylvia offers insights into commercialization strategies.
Mike Gibbs - Senior Advisor. Mike advises on regulatory matters and clinical development.
Ronald Lee Krall, MD - Senior Advisor. Ronald brings clinical expertise to the advisory board.
Suzanne Hendrix, PhD - Advisor. Suzanne provides scientific insights and guidance.
Richard Sudek, PhD - Advisor. Richard offers expertise in technology commercialization.
Carol Criner - Advisor. Carol advises on operational strategies.
Laurie Heilmann - Venture Partner. Laurie joined in January 2026 and has extensive experience in healthcare technology and life sciences.
To pitch Propel Bio Partners, startups should use the contact form available on their website at propelbio.com. It is essential to include a comprehensive pitch deck that outlines the business model, technology, market opportunity, and team qualifications. The firm appreciates detailed information that demonstrates the startup's potential for growth and impact.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In 2022, Propel Bio Partners commenced operations, focusing on investments in life science companies. The firm is currently raising a $150 million fund to support its investment activities.
In January 2026, Propel Bio Partners announced the addition of Laurie Heilmann as a Venture Partner, enhancing the firm's strategic leadership in healthcare technology.
Propel Bio Partners has been listed on the Medical Technology Enterprise Consortium of Southern California's investor directory, indicating its growing presence in the life sciences investment community.
What are Propel Bio Partners' investment criteria?
Propel Bio Partners invests in life science companies that are developing groundbreaking therapies and technologies. The firm focuses on biotech and healthcare sectors, particularly those with disruptive innovations that can significantly impact human health.
How can startups apply or pitch to Propel Bio Partners?
Startups can pitch to Propel Bio Partners through their website at propelbio.com. It is recommended to include a detailed overview of the business model, technology, and the team in the pitch deck.
What makes Propel Bio Partners different from other venture capital firms?
Propel Bio Partners distinguishes itself by providing not only financial investment but also access to a network of medical experts and operational advisors. This support helps portfolio companies navigate the complexities of the life sciences landscape.
What is the geographic scope of Propel Bio Partners' investments?
The firm primarily focuses on investments within the United States, targeting life science companies that are advancing innovative therapies and technologies.
What is the typical check size for investments made by Propel Bio Partners?
While specific check sizes are not disclosed, Propel Bio Partners is known to provide substantial financial backing to support the growth of its portfolio companies.
What kind of post-investment involvement does Propel Bio Partners have?
Propel Bio Partners actively engages with its portfolio companies by providing access to a network of advisors and experts, helping them achieve their vision and navigate challenges in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.